Stock KALA KALA BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News KALA BIO, Inc.

Equities

KALA

US4831192020

Market Closed - Nasdaq
Other stock markets
 04:30:01 2024-05-10 pm EDT 		5-day change 1st Jan Change
6.9 USD +2.79% Intraday chart for KALA BIO, Inc. -1.53% -1.43%
Apr. 02 HC Wainwright Trims KALA BIO's Price Target to $21 From $22, Keeps Buy Rating MT
Mar. 29 KALA BIO, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
HC Wainwright Trims KALA BIO's Price Target to $21 From $22, Keeps Buy Rating
MT
KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
AQ
KALA BIO, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
KALA BIO, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
AQ
KALA BIO, Inc. announced that it expects to receive $8.599799 million in funding from Baker Bros. Advisors LP
CI
North American Morning Briefing : Stocks Struggle After New Records
DJ
North American Morning Briefing : Inflation -2-
DJ
KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference
AQ
KALA BIO to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
AQ
KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
KALA BIO, Inc. announced that it expects to receive $1.999824 million in funding
CI
HC Wainwright Adjusts Kala Pharmaceuticals Price Target to $22 From $24, Maintains Buy Rating
MT
Wedbush Lowers Kala Pharmaceuticals' PT to $22 From $39, Moves US Launch Estimate for Lead Asset KPI-012; Maintains Outperform Rating
MT
KALA BIO, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update
AQ
KALA BIO Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
AQ
KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference
AQ
KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KALA Stock
  4. News KALA BIO, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW